GeneLink, Inc. (GNLKQ) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 18, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerGeneLink, Inc. (GNLKQ) trades at $0.00004. GeneLink, Inc. specializes in personalized health solutions, offering DNA assessment services, custom supplements, and skincare products. Founded in 1994, the company operates in the biotechnology sector, focusing on individualized wellness approaches. Sector: Healthcare.
Price as of · Last analyzed: Mar 18, 2026Analyst Coverage for GNLKQ: GNLKQ does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
GeneLink, Inc. (GNLKQ) Healthcare & Pipeline Overview
GeneLink, Inc., founded in 1994, provides personalized health solutions through DNA assessment services, custom supplements, and skincare products. Operating in the biotechnology sector, the company focuses on individualized wellness, but faces challenges with profitability and OTC market risks, reflected in its negative P/E ratio and significant beta.
What Is the Investment Thesis for GNLKQ?
Investing in GeneLink, Inc. (GNLKQ) presents a high-risk, high-reward scenario. The company's focus on personalized health solutions through DNA assessment services aligns with growing consumer interest in preventative and individualized healthcare. However, the company's negative P/E ratio and significant beta of -157.42 indicate substantial financial instability and volatility. Growth catalysts may include expanding its product line and strategic partnerships to broaden market reach. Key value drivers would be achieving profitability and demonstrating sustainable revenue growth. The OTC market listing introduces additional risks related to liquidity and regulatory oversight. Investors should carefully weigh the potential for growth in the personalized health market against the company's current financial challenges and the risks associated with OTC trading.
Based on FMP financials and quantitative analysis
GNLKQ Key Highlights
Market Cap of $0.00B indicates a micro-cap company with limited resources and higher volatility.
- P/E Ratio of -0.00 reflects that the company is not currently profitable.
- Profit Margin of -142.9% demonstrates significant losses relative to revenue.
- Gross Margin of 21.8% suggests some ability to generate profit from sales before operating expenses.
- Beta of -157.42 indicates an inverse correlation to the market, but also suggests high volatility and potential instability.
Who Are GNLKQ's Competitors?
GNLKQ is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| ICCC ImmuCell Corporation | $9.75 | +1.56% | $88.2M | 79 5-pillar |
| RLYB Rallybio Corporation | $17.08 | +1.91% | $90.6M | 83 5-pillar |
| ALPX Alopexx, Inc. | $9.96 | 0.00% | $119M | 65 5-pillar |
| ORMP Oramed Pharmaceuticals Inc. | $4.49 | +0.22% | $184M | 76 5-pillar |
| ANTX AN2 Therapeutics, Inc. | $5.71 | +1.60% | $206M | 67 5-pillar |
| NAGE Niagen Bioscience Inc | $2.79 | +4.10% | $222M | 69 5-pillar |
| QTTB Q32 Bio Inc. | $8.23 | -0.24% | $245M | 67 5-pillar |
| CRMD CorMedix Inc. | $7.19 | -3.10% | $564M | 94 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are GNLKQ's Key Strengths?
Personalized health solutions based on DNA assessment.
- Customized supplement formulations.
- Proprietary technology for DNA analysis.
- Direct-to-consumer sales model.
What Are GNLKQ's Weaknesses?
Negative profit margin and financial instability.
- Limited market capitalization.
- OTC market listing with associated risks.
- Dependence on a niche market.
What Are the Key Risks for GNLKQ?
Financial-distress signal — its Altman Z-Score of -35.02 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Increased competition from established players in the biotechnology sector.
- Regulatory changes affecting DNA assessment and supplement industries.
- Negative profit margin and financial instability.
- OTC market listing with associated risks.
What Threats Does GNLKQ Face?
- Competition from established players in the biotechnology sector.
- Regulatory changes affecting DNA assessment and supplement industries.
- Economic downturn impacting consumer spending on personalized health solutions.
- Negative publicity or scientific studies questioning the effectiveness of DNA-based personalized health.
What Are GNLKQ's Competitive Advantages?
- Proprietary DNA assessment technology.
- Customized supplement formulations based on genetic information.
- Personalized skincare product line.
- Focus on individualized health solutions.
What Does GNLKQ Do?
GeneLink, Inc., established in 1994 and based in Orlando, Florida, operates within the healthcare sector, specifically in biotechnology. The company focuses on personalized health solutions, primarily offering 12-gene DNA assessment services. These assessments are designed to provide insights into an individual's genetic predispositions, which GeneLink then uses to formulate health custom supplements tailored to the individual's needs. In addition to supplements, GeneLink formulates and markets a line of skin care products also designed with personalized health in mind. GeneLink's business model centers around leveraging genetic information to create individualized health and wellness products. The company caters to consumers interested in proactive and personalized healthcare solutions. However, it currently faces challenges related to profitability, as indicated by its negative profit margin of -142.9%.
What Products and Services Does GNLKQ Offer?
- Offers 12-gene DNA assessment services to provide insights into individual genetic predispositions.
- Formulates health custom supplements based on DNA assessment results.
- Develops and markets a line of skin care products.
- Provides personalized health solutions tailored to individual needs.
- Utilizes genetic information to create individualized health and wellness products.
- Caters to consumers interested in proactive and personalized healthcare solutions.
How Does GNLKQ Make Money?
- Generates revenue through the sale of DNA assessment services.
- Generates revenue through the sale of custom supplements formulated based on DNA assessment results.
- Generates revenue through the sale of skin care products.
- Focuses on direct-to-consumer sales through online channels.
What Industry Does GNLKQ Operate In?
GeneLink, Inc. operates in the rapidly evolving biotechnology sector, which is characterized by innovation and personalized medicine. The market for personalized health solutions, including DNA assessment and custom supplements, is growing, driven by increasing consumer awareness and technological advancements. However, the industry is also highly competitive, with numerous companies offering similar services. GeneLink faces competition from established players and emerging startups. The company's success depends on its ability to differentiate its products, effectively market its services, and navigate the complex regulatory landscape of the healthcare industry.
Who Are GNLKQ's Key Customers?
- Individuals interested in personalized health and wellness solutions.
- Consumers seeking proactive healthcare options.
- People looking for customized supplements and skincare products.
- Customers who value genetic insights for health management.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Key Financial Metrics
Return on equity for GeneLink, Inc. stands at 147.3%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.42 means current liabilities exceed short-term assets, a liquidity point worth watching.
Company Profile
GeneLink, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Orlando, US. The company is led by CEO Bernard L. Kasten Jr.. GNLKQ has traded publicly since 1998.
Financial Health
GeneLink, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -35.02 places it in the distress zone, a signal of elevated financial risk.
GNLKQ Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
GNLKQ Latest News
No recent news available for GNLKQ.
GNLKQ Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for GNLKQ.
Price Targets
Wall Street price target analysis for GNLKQ.
GNLKQ MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for GNLKQ; grades run from A+ (80-100) to F (below 30).
Leadership: Bernard L. Kasten Jr.
CEO
Bernard L. Kasten Jr. serves as the CEO of GeneLink, Inc. His background includes experience in the healthcare and biotechnology sectors. He has held various leadership positions in companies focused on developing and marketing innovative health solutions. His expertise lies in strategic planning, product development, and market expansion. He is responsible for guiding GeneLink's overall strategy and ensuring the company's growth and profitability.
Track Record: Under Bernard L. Kasten Jr.'s leadership, GeneLink has focused on expanding its product line and enhancing its direct-to-consumer marketing efforts. Key milestones include the development of new DNA assessment services and the launch of personalized skincare products. However, the company continues to face challenges related to profitability and financial stability.
GNLKQ OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that GeneLink may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may be subject to less regulatory oversight compared to companies listed on major exchanges like NYSE or NASDAQ. Investing in companies on the OTC Other tier carries significant risks due to the potential for fraud, lack of transparency, and limited liquidity.
- OTC Tier: OTC Other
- Limited Liquidity: Difficulty in buying or selling shares due to low trading volume.
- Lack of Transparency: Limited financial disclosure and regulatory oversight.
- Price Volatility: High price fluctuations due to speculative trading and limited market depth.
- Potential for Fraud: Increased risk of fraudulent activities due to less stringent listing requirements.
- Going Concern Risk: Uncertainty about the company's ability to continue operating due to financial instability.
- Verify the company's financial statements and audit reports.
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's regulatory compliance and legal standing.
- Monitor the company's trading volume and price activity.
- Consult with a qualified financial advisor before investing.
- Understand the risks associated with OTC trading.
- Company has been in operation since 1994.
- Offers DNA assessment services, custom supplements, and skincare products.
- Has a CEO in place.
- Operates in the healthcare sector.
GeneLink, Inc. Healthcare Stock: Key Questions Answered
What do analysts say about GNLKQ stock?
Currently, there is no available analyst coverage for GNLKQ stock. Given its OTC listing and micro-cap status with a market cap of $0.00B, the stock is unlikely to be actively tracked by major financial analysts. Investors should rely on their own due diligence and research to assess the company's prospects and risks.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Financial data is based on the most recent available information.
- OTC market data may be limited and subject to change.